Loading
A phase 2 trial of Cetuximab in head and neck squamous cell carcinoma, run by Shanghai Institute Of Biological Products, now recruiting.
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06194656 by Shanghai Institute Of Biological Products, with 81 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-07-30. Interventions recorded: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cetuximab, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.